Physician profile
Kurt Davey
NPI 1104991116
$1,712.76
in general payments reported to CMS, 2019-2025
28 companies · $309 in 2025
The $309 reported for 2025 was more than what 85% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $20.30 · 2021: $354 · 2022: $409 · 2023: $259 · 2024: $139 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $395.35 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $136.77 | 2019-2025 | |
| Seqirus USA INC | $125.27 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Sanofi Pasteur INC. | $120.21 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $92.74 | 2024-2025 | |
| Kaleo, INC. | $81.13 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $69.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $67.63 | 2019 | |
| Tris Pharma INC | $66.97 | 2021-2023 | Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $61.79 | 2022-2025 | Flumist Quadrivalent, Fasenra |
| Merck Sharp & Dohme LLC | $58.86 | 2022-2025 | Rotateq, Vaxneuvance, Gardasil 9 |
| Ironshore Pharmaceuticals INC. | $57.25 | 2019-2022 | |
| Hologic Sales and Service, LLC | $50.02 | 2019-2025 | Aptima, Third Wave |
| Neos Therapeutics, LP | $49.50 | 2022 | |
| Genentech USA, INC. | $34.97 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $32.52 | 2021 | |
| Glaxosmithkline, LLC. | $25.63 | 2019-2021 | |
| Kyowa Kirin, INC. | $20.57 | 2023 | Crysvita |
| Sobi, INC | $20.32 | 2023 | |
| Corium, LLC | $20.02 | 2022 | |
| Acadia Pharmaceuticals INC | $19.09 | 2025 | Daybue |
| Sarepta Therapeutics, INC. | $16.93 | 2022 | |
| Biomarin Pharmaceutical INC. | $16.85 | 2023 | Voxzogo 1.2mg |
| Ultragenyx Pharmaceutical INC. | $16.11 | 2022 | |
| Shire North American Group INC | $14.51 | 2019 | |
| Neurelis, INC. | $14.47 | 2021 | |
| Alk-Abello, INC | $14.05 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.46 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Davey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.